Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease.

Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Abstract Text:

Omid Hamid,Jolie C Solomon,Ronald Scotland,Marile Garcia,Shirley Sian,Wei Ye,Susan L Groshen,Jeff S Weber,

PURPOSE: We attempted to augment immunity to melanoma antigens using interleukin-12 (IL-12) with aluminum hydroxide (alum) for sustained release or granulocyte macrophage colony-stimulating factor (GM-CSF) added to a multipeptide vaccine. EXPERIMENTAL DESIGN: Sixty patients with high-risk resected melanoma were randomized to receive melanoma peptides gp100(209-217) (210M), MART-1(26-35) (27L), and tyrosinase(368-376) (370D) with adjuvant Montanide ISA 51 and either IL-12 at 30 ng/kg with alum (group A), IL-12 at 100 ng/kg with alum (group B), or IL-12 at 30 ng/kg with 250 mug GM-CSF (group C). RESULTS: Three patients had stage IIC (5%), 50 had stage III (83%), and 7 had stage IV (12%) melanoma. Most toxicities were grade 1/2 and resolved rapidly. Significant toxicity included grade 3 colitis and visual changes and grade 3 headache resolving after stopping IL-12 but continuing peptide vaccine. A higher rate of post-vaccine 6-month immune response to gp100 and MART-1 was observed in group A (15 of 19) or B (19 of 20) that received IL-12 plus alum versus group C with IL-12/GM-CSF (4 of 21; P < 0.001). Post-vaccine enzyme-linked immunospot response rates to peptide analogues in group B were higher than group A (P = 0.031 for gp100 and P = 0.010 for MART-1); both were higher than group C (P < 0.001 for gp100 and P < 0.026 for MART-1). With a median of 24 months of follow-up, 23 patients have relapsed. Post-vaccine immune response to MART-1 was associated with relapse-free survival (P = 0.012). CONCLUSIONS: IL-12 with alum augmented an immune response to melanoma antigens compared with IL-12 with GM-CSF. Immune response was associated with time to relapse.

Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Publishing Authors By Initials

O Hamid,JC Solomon,R Scotland,M Garcia,S Sian,W Ye,SL Groshen,JS Weber,

For similar complex mixtures: biological products: vaccines: vaccines, subunit research abstracts see: complex mixtures: biological products: vaccines: vaccines, subunit research

PUBMED ID PMID:

MEDLINE DATE:

Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Clinical cancer research : an official journal of

VOLUME: 13

Page Numbers: 215-22

Journal Abbreviation: Clin. Cancer Res.

ISSN: 1078-0432

DAY: 1

MONTH: Jan

YEAR: 2007

Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502500

Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Keywords Mesh Terms:

KEYWORDS: Vaccines, Subunit

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Information

Substance Name: Interleukin-12

Registry Number: 187348-17-0

Grant and Affiliation Information for Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease.

AFFILIATION: The Angeles Clinic and Research Institute, Santa Monica, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA90751-01

ACRONYM: CA

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease Related Publications

• ATP synthase--the structure of the stator stalk.
• Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease.
• Assessment of contamination by polychlorinated biphenyls and aliphatic and aromatic hydrocarbons in sediments of the Santos and São Vicente Estuary System, São Paulo, Brazil.
• Bowel symptoms in women planning surgery for pelvic organ prolapse.
• Chemokines: inflammatory mediators of atherosclerosis.
• Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety.
• Controlling the electrochemically active area of carbon fiber microelectrodes by the electrodeposition and selective removal of an insulating photoresist.
• Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury.
• Differential localization of the Dictyostelium kinase DPAKa during cytokinesis and cell migration.
• Effect of rhBMP-2 on guided bone regeneration in humans.
• Effects of methylmalonyl-CoA mutase gene knockouts on erythromycin production in carbohydrate-based and oil-based fermentations of Saccharopolyspora erythraea.
• Electrochemical investigation of Pb2+ binding and transport through a polymerized crystalline colloidal array hydrogel containing benzo-18-crown-6.
• Endoanal ultrasound findings and fecal incontinence symptoms in women with and without recognized anal sphincter tears.
• FDA regulation of allogeneic islets as a biological product.
• High-throughput method for lipophilicity measurement.
• Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements.
• Inflammatory mediators in atherosclerotic vascular disease.
• Inhibition of inflammatory endothelial responses by a pathway involving caspase activation and p65 cleavage.
• Perfusion MRI in CNS disease: current concepts.
• Physical activity in women planning sacrocolpopexy.
• RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.
• Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.
• Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B.
• Renal effects of opioid exposure: considerations for therapeutic use.
• Rydberg fingerprint spectroscopy of hot molecules: structural dispersion in flexible hydrocarbons.
• Selective cancer cell killing by alpha-tocopheryl succinate.
• Simultaneous maximization of cell permeabilization and viability in single-cell electroporation using an electrolyte-filled capillary.
• TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation.
• The conserved TFLK motif of mammary-associated serum amyloid A3 is responsible for up-regulation of intestinal MUC3 mucin expression in vitro.
• alpha-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing NF-kappa B mobilization.